
Opinion|Videos|February 14, 2025
MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors
Panelists provide an overview of the current landscape of induction therapies for mantle cell lymphoma (MCL), discussing the role of Bruton tyrosine kinase (BTK) inhibitors in this setting and the use of aggressive induction therapies.
Advertisement
Episodes in this series

- Provide an overview of the current landscape of induction therapies for MCL. What role do BTK inhibitors have in this landscape?
- Aggressive induction therapy
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
3
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
4
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
5

















































